Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. - Wikidata - awgldk - TriplyDB

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

http://www.wikidata.org/entity/Q38628641

about

Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment Ongoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray?Repurposing of approved cardiovascular drugs Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.Muscle wasting: an overview of recent developments in basic research.Cancer cachexia, mechanism and treatment Muscle wasting and cachexia in heart failure: mechanisms and therapies.Losartan treatment attenuates tumor-induced myocardial dysfunction Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia On the Rate of Synthesis of Individual Proteins within and between Different Striated Muscles of the Rat.Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia.Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.Cardiac Cachexia: Perspectives for Prevention and Treatment.Malnutrition and Cachexia in Heart Failure.Developing models for cachexia and their implications in drug discovery.Pay attention to cardiac remodeling in cancer cachexia.Tumor inoculation site affects the development of cancer cachexia and muscle wasting.Muscle wasting in heart failure : The role of nutrition.Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.Influence of cancer cachexia on drug liver metabolism and renal elimination in rats Febuxostat improves outcome in a rat model of cancer cachexia.Left ventricular mass correlates with lean body mass in patients with disease-associated wasting.Formoterol in the treatment of experimental cancer cachexia: effects on heart function Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Minocycline attenuates cardiac dysfunction in tumor-burdened mice.Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.Cardiac muscle wasting in individuals with cancer cachexia.Therapeutic considerations of sarcopenia in heart failure patients.Increased hypoxia-inducible factor-1α in striated muscle of tumor-bearing mice.Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.Muscle wasting and sarcopenia in heart failure and beyond: update 2017.Subcutaneous Ehrlich Ascites Carcinoma mice model for studying cancer-induced cardiomyopathy.

P2860

Q26775254-E9DBEB60-C59B-45F0-8741-E18C85962C8C Q26800197-E39C10DC-73C9-4D15-A2FF-8F535E4D9AE7 Q28074453-74C268AD-DCB2-49C8-9EB9-2948F05BA039 Q33741091-24434E50-E6F9-48EC-927C-6C40950380A3 Q34156942-AEEEFBA9-FCD5-4DA8-8130-5942A3DE3246 Q34669440-975ED6F8-34E1-4D28-B2D0-705B246E608B Q34681621-ACBEEB3A-6995-4524-9561-AED32414835E Q35931497-67541072-01CF-427A-A300-9266B0974517 Q35958613-609C0FF5-E824-4517-B7E4-3C976CAAFBEB Q36293597-283C919F-9C76-4E0C-AA43-D0E75F34493A Q36528019-9485882C-03AD-4136-907E-A80F536DE0AC Q36692110-4C9AA558-A211-4E48-8B2C-B37D4FD3C29D Q37594528-8B45985A-E0EE-48FF-8CF8-BD9F647AC6D6 Q38337032-D0FA3EF9-0938-4CE9-AB0E-DA37FC1F5B9A Q38451282-CBB559D0-B417-44B3-AD52-B894883A7F6A Q38815915-C0371201-8ED5-4CBF-ACCE-53492FD145DB Q38870440-6B51DE33-E608-4584-BB44-018509D063EA Q38985792-4481B906-768E-4D36-8B84-8682856C6112 Q39726480-A46FA436-7C78-4DC3-B8A2-388BD13E8CC2 Q40771392-385931F9-6429-45E8-A3B7-91DD3E69FBF6 Q41769219-E9301C90-2770-41A4-8FBA-2A06055FFDFE Q42028361-9519B664-694B-4D4A-AACB-269136CDCA9A Q42062172-C2F5EF0F-96DF-4AC1-8292-E4511F369FAC Q42257917-CE2BC6EE-3C37-40FD-9C56-3B81EE5C11DF Q42398016-70C272F8-8A1C-4714-A778-589D5E40AD09 Q42860182-43413207-DDDC-49A3-8B01-B32459D8212E Q47214314-E0F3D8F3-B85E-4C1D-B4DC-8AE4E03AC87C Q47445814-93A17C6C-09A6-40ED-98F4-D3158E2E95D5 Q47747144-ABFE6798-DCAB-45EC-8623-A06DA0E6B992 Q47938781-C0A0EB4E-FFBB-438D-90A3-5504A586208E Q48113573-59EEBC86-19FF-44D0-A7CE-306E5E82324E Q49183956-50FE3494-6B84-4C4B-A389-6C63EAA09DCE Q55002400-8CD9BB02-883C-484F-848A-983481F765CC

P2860

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

http://www.wikidata.org/entity/Q38628641

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

@en

type

label

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

@en

prefLabel

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

@en

P1433

Q38628641-91130E88-E0E5-4B72-9674-8ABE36A18188

P1476

Q38628641-639C17DB-2632-4ACC-9605-64701D4A0298

P2093

Q38628641-076CEABE-2F12-4B24-A075-F79E816F65CA

Q38628641-0E5EEC34-5BBD-44D5-973E-0FDBF53B9B66

Q38628641-0F76B34B-9E3A-4124-8D5D-BDB78347492F

Q38628641-1E5DF906-A15A-4969-95EA-0541069D1E83

Q38628641-30E63ADD-952B-4024-AF1E-CF055C6B6992

Q38628641-48DA8C68-B654-4746-847B-43D95FE6BA9E

Q38628641-5DE07502-80E2-43CB-A675-223976455CF7

Q38628641-615B2064-E33B-4E59-A237-B8C886C81EA8

Q38628641-712258FA-979C-4224-B896-A659BFA57FBA

Q38628641-769971B3-F2E6-47D7-A352-8272EC8DD815

P2860

Q38628641-05A49FA4-09BF-42BA-A5C6-E86B3F2DD0CC

Q38628641-0FF714FB-951B-4062-92F9-41BF3167BDEF

Q38628641-10BD9203-8178-4B6F-AD2F-7B5E7C3A0625

Q38628641-16EDFB08-6C1F-4A32-980C-81A1915E4D3B

Q38628641-206881D6-AE6A-4A1D-A36C-AA7DC831A938

Q38628641-25C88EDF-1352-43B7-A69B-46DF1493C52A

Q38628641-38D7F9DF-A72D-4A8C-8354-553B59C0304A

Q38628641-41D74AD0-2EE1-422B-B66C-5BA2536CA3E0

Q38628641-43B23EEA-AC51-4CEA-BCDC-91F05983EF8C

Q38628641-4BBDE316-B250-4D73-8014-723343E90F53

P304

Q38628641-535D5D28-7BE9-4496-9570-9F8354E44114

P31

Q38628641-2788B7B3-19A1-4612-8E9D-0B4EA46FEC94

P356

Q38628641-B6E116C1-D3E6-4796-BA82-6F463DAB6198

P433

Q38628641-2855E4B0-35A6-4AE4-8644-539CD302FFD7

P478

Q38628641-23A47D38-44AC-4AE4-B730-724CE7FAEED4

P50

Q38628641-10E72BBB-C611-4A60-B047-70F37E7613CD

Q38628641-12EE8B0A-9404-462C-B30C-621A333999BB

Q38628641-17E7BF09-5152-449A-ABFB-C22A2BFF5478

Q38628641-292F59E6-942A-4975-82B2-19FB2EFFE6D5

Q38628641-452BB30F-CA59-4CF6-9C65-287D24CBCB82

Q38628641-92EDFA9E-7BD7-41E6-A944-6C79F2D54020

Q38628641-A1C5270E-1A95-458A-AEA7-B32836ACCC93

Q38628641-FF9961C5-9DC0-4E7A-BD9C-C95D9CD6F9E4

P577

Q38628641-12DF9B80-B884-405B-ADCC-F4B89F392CA2

P698

Q38628641-D6A8C58B-2490-4098-9D48-0E9548709FF7

P921

Q38628641-266142AC-9C4C-4333-90C4-799FBC6F03B5

P932

Q38628641-076BF9DD-D34C-4F63-B01C-31CD484E64BE

P356

P1433

European Heart Journal

P1476

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

@en

P2093

Aleksandra Grzesiak

http://www.w3.org/2001/XMLSchema#string

Andrew J S Coats

http://www.w3.org/2001/XMLSchema#string

Anika Tschirner

http://www.w3.org/2001/XMLSchema#string

Arash Haghikia

http://www.w3.org/2001/XMLSchema#string

Celine Latouche

http://www.w3.org/2001/XMLSchema#string

Denise Hilfiker-Kleiner

http://www.w3.org/2001/XMLSchema#string

Gabor Földes

http://www.w3.org/2001/XMLSchema#string

Jochen Springer

http://www.w3.org/2001/XMLSchema#string

John Beadle

http://www.w3.org/2001/XMLSchema#string

Josep M Argiles

http://www.w3.org/2001/XMLSchema#string

P2860

Ciclesonide versus other inhaled corticosteroids for chronic asthma in children

Myostatin regulates cardiomyocyte growth through modulation of Akt signaling

Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure

NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression

Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity

Cachexia: a new definition.

Mechanisms of cancer cachexia.

ABC of palliative care. Anorexia, cachexia, and nutrition.

Cachexia as a major underestimated and unmet medical need: facts and numbers

PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription

P304

932-941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHT302

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Frederic Jaisser

Stephan von Haehling

Berthold Hocher

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23990596

http://www.w3.org/2001/XMLSchema#string

P921

P932

3977133

http://www.w3.org/2001/XMLSchema#string